Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis

Ryan D. Geraets, Seung Yon Koh, Michelle L. Hastings, Tammy L Kielian, David A. Pearce, Jill M. Weimer

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

The Neuronal Ceroid Lipofuscinoses (NCLs) are a family of autosomal recessive neurodegenerative disorders that annually affect 1:100,000 live births worldwide. This family of diseases results from mutations in one of 14 different genes that share common clinical and pathological etiologies. Clinically, the diseases are subcategorized into infantile, late-infantile, juvenile and adult forms based on their age of onset. Though the disease phenotypes may vary in their age and order of presentation, all typically include progressive visual deterioration and blindness, cognitive impairment, motor deficits and seizures. Pathological hallmarks of NCLs include the accumulation of storage material or ceroid in the lysosome, progressive neuronal degeneration and massive glial activation. Advances have been made in genetic diagnosis and counseling for families. However, comprehensive treatment programs that delay or halt disease progression have been elusive. Current disease management is primarily targeted at controlling the symptoms rather than "curing" the disease. Recognizing the growing need for transparency and synergistic efforts to move the field forward, this review will provide an overview of the therapeutic approaches currently being pursued in preclinical and clinical trials to treat different forms of NCL as well as provide insight to novel therapeutic approaches in development for the NCLs.

Original languageEnglish (US)
Article number414
JournalOrphanet Journal of Rare Diseases
Volume11
Issue number1
DOIs
StatePublished - Apr 16 2016

Fingerprint

Neuronal Ceroid-Lipofuscinoses
Ceroid
Genetic Counseling
Live Birth
Blindness
Therapeutics
Disease Management
Lysosomes
Age of Onset
Neuroglia
Neurodegenerative Diseases
Disease Progression
Seizures
Clinical Trials
Phenotype
Mutation
Genes

Keywords

  • Antisense oligonucleotides
  • Autophagy modulators
  • Batten disease
  • Enzyme replacement therapy
  • Gene therapy
  • Lysosomal modulators
  • Palmitoyl-Protein Thioesterase 1
  • RNA modulating therapies
  • Stem cell therapy
  • Translational research
  • Tripeptidyl peptidase 1

ASJC Scopus subject areas

  • Genetics(clinical)
  • Pharmacology (medical)

Cite this

Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis. / Geraets, Ryan D.; Koh, Seung Yon; Hastings, Michelle L.; Kielian, Tammy L; Pearce, David A.; Weimer, Jill M.

In: Orphanet Journal of Rare Diseases, Vol. 11, No. 1, 414, 16.04.2016.

Research output: Contribution to journalReview article

Geraets, Ryan D. ; Koh, Seung Yon ; Hastings, Michelle L. ; Kielian, Tammy L ; Pearce, David A. ; Weimer, Jill M. / Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis. In: Orphanet Journal of Rare Diseases. 2016 ; Vol. 11, No. 1.
@article{ff4ef1af850d439ba9212fe6bcda8ee6,
title = "Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis",
abstract = "The Neuronal Ceroid Lipofuscinoses (NCLs) are a family of autosomal recessive neurodegenerative disorders that annually affect 1:100,000 live births worldwide. This family of diseases results from mutations in one of 14 different genes that share common clinical and pathological etiologies. Clinically, the diseases are subcategorized into infantile, late-infantile, juvenile and adult forms based on their age of onset. Though the disease phenotypes may vary in their age and order of presentation, all typically include progressive visual deterioration and blindness, cognitive impairment, motor deficits and seizures. Pathological hallmarks of NCLs include the accumulation of storage material or ceroid in the lysosome, progressive neuronal degeneration and massive glial activation. Advances have been made in genetic diagnosis and counseling for families. However, comprehensive treatment programs that delay or halt disease progression have been elusive. Current disease management is primarily targeted at controlling the symptoms rather than {"}curing{"} the disease. Recognizing the growing need for transparency and synergistic efforts to move the field forward, this review will provide an overview of the therapeutic approaches currently being pursued in preclinical and clinical trials to treat different forms of NCL as well as provide insight to novel therapeutic approaches in development for the NCLs.",
keywords = "Antisense oligonucleotides, Autophagy modulators, Batten disease, Enzyme replacement therapy, Gene therapy, Lysosomal modulators, Palmitoyl-Protein Thioesterase 1, RNA modulating therapies, Stem cell therapy, Translational research, Tripeptidyl peptidase 1",
author = "Geraets, {Ryan D.} and Koh, {Seung Yon} and Hastings, {Michelle L.} and Kielian, {Tammy L} and Pearce, {David A.} and Weimer, {Jill M.}",
year = "2016",
month = "4",
day = "16",
doi = "10.1186/s13023-016-0414-2",
language = "English (US)",
volume = "11",
journal = "Orphanet Journal of Rare Diseases",
issn = "1750-1172",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis

AU - Geraets, Ryan D.

AU - Koh, Seung Yon

AU - Hastings, Michelle L.

AU - Kielian, Tammy L

AU - Pearce, David A.

AU - Weimer, Jill M.

PY - 2016/4/16

Y1 - 2016/4/16

N2 - The Neuronal Ceroid Lipofuscinoses (NCLs) are a family of autosomal recessive neurodegenerative disorders that annually affect 1:100,000 live births worldwide. This family of diseases results from mutations in one of 14 different genes that share common clinical and pathological etiologies. Clinically, the diseases are subcategorized into infantile, late-infantile, juvenile and adult forms based on their age of onset. Though the disease phenotypes may vary in their age and order of presentation, all typically include progressive visual deterioration and blindness, cognitive impairment, motor deficits and seizures. Pathological hallmarks of NCLs include the accumulation of storage material or ceroid in the lysosome, progressive neuronal degeneration and massive glial activation. Advances have been made in genetic diagnosis and counseling for families. However, comprehensive treatment programs that delay or halt disease progression have been elusive. Current disease management is primarily targeted at controlling the symptoms rather than "curing" the disease. Recognizing the growing need for transparency and synergistic efforts to move the field forward, this review will provide an overview of the therapeutic approaches currently being pursued in preclinical and clinical trials to treat different forms of NCL as well as provide insight to novel therapeutic approaches in development for the NCLs.

AB - The Neuronal Ceroid Lipofuscinoses (NCLs) are a family of autosomal recessive neurodegenerative disorders that annually affect 1:100,000 live births worldwide. This family of diseases results from mutations in one of 14 different genes that share common clinical and pathological etiologies. Clinically, the diseases are subcategorized into infantile, late-infantile, juvenile and adult forms based on their age of onset. Though the disease phenotypes may vary in their age and order of presentation, all typically include progressive visual deterioration and blindness, cognitive impairment, motor deficits and seizures. Pathological hallmarks of NCLs include the accumulation of storage material or ceroid in the lysosome, progressive neuronal degeneration and massive glial activation. Advances have been made in genetic diagnosis and counseling for families. However, comprehensive treatment programs that delay or halt disease progression have been elusive. Current disease management is primarily targeted at controlling the symptoms rather than "curing" the disease. Recognizing the growing need for transparency and synergistic efforts to move the field forward, this review will provide an overview of the therapeutic approaches currently being pursued in preclinical and clinical trials to treat different forms of NCL as well as provide insight to novel therapeutic approaches in development for the NCLs.

KW - Antisense oligonucleotides

KW - Autophagy modulators

KW - Batten disease

KW - Enzyme replacement therapy

KW - Gene therapy

KW - Lysosomal modulators

KW - Palmitoyl-Protein Thioesterase 1

KW - RNA modulating therapies

KW - Stem cell therapy

KW - Translational research

KW - Tripeptidyl peptidase 1

UR - http://www.scopus.com/inward/record.url?scp=84966440677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966440677&partnerID=8YFLogxK

U2 - 10.1186/s13023-016-0414-2

DO - 10.1186/s13023-016-0414-2

M3 - Review article

C2 - 27083890

AN - SCOPUS:84966440677

VL - 11

JO - Orphanet Journal of Rare Diseases

JF - Orphanet Journal of Rare Diseases

SN - 1750-1172

IS - 1

M1 - 414

ER -